163 related articles for article (PubMed ID: 24926635)
1. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report].
Durand M; Logerot S; Fonrose X; Schir E
Therapie; 2014; 69(2):163-8. PubMed ID: 24926635
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
5. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
6. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Lai YC; Lin PC; Lai JI; Hsu SY; Kuo LC; Chang SC; Wang WS
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):461-6. PubMed ID: 21726497
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Kunimasa K; Yoshioka H; Iwasaku M; Nishiyama A; Korogi Y; Masuda G; Takaiwa T; Ishida T
Intern Med; 2012; 51(4):431-4. PubMed ID: 22333382
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
11. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
12. Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Toba H; Sakiyama S; Takizawa H; Tangoku A
J Med Invest; 2016; 63(1-2):149-51. PubMed ID: 27040072
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
14. [Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Ohashi Y; Suzuki K; Sakurai M; Ishikawa H; Onishi T; Nakagaki S; Kato T; Shino M; Naito T; Takahashi T; Yamamoto N
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1307-11. PubMed ID: 20647715
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
16. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
17. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
[TBL] [Abstract][Full Text] [Related]
18. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Maruyama K; Chinda J; Kuroshima T; Kabara M; Nakagawa N; Fujino T; Yamamoto Y; Ohsaki Y; Ogawa Y; Hasebe N
Intern Med; 2015; 54(7):823-6. PubMed ID: 25832950
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Takeda M; Okamoto I; Fukuoka M; Nakagawa K
J Clin Oncol; 2010 Jun; 28(17):e273-4. PubMed ID: 20385983
[No Abstract] [Full Text] [Related]
[Next] [New Search]
